NVO Novo Nordisk

By Maryam Cockar

Novo Nordisk AS (NVO) said Tuesday that the U.S. Food and Administration has approved its Ozempic semaglutide injection which helps treat adults with type 2 diabetes.

The Danish pharmaceutical said the approval for Ozempic was based on results from a clinical trial program and follows a positive recommendation from the FDA's advisory committee in October.

Ozempic was approved for use in two dosages of 0.5 milligrams and 1 milligram and will be launched as a pre-filled pen device, the company said.

Novo Nordisk added that it will use part of the approved requirements for the drug to conduct a trial on adolescents under 18 years old.

Write to Maryam Cockar at maryam.cockar@dowjones.com

(END) Dow Jones Newswires

December 05, 2017 13:44 ET (18:44 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.